Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8⁺ T cells

References

• Lizee G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P. Harnessing the power of the immune system to target cancer. Annu Rev Med 2013; 64:71-90; PMID:23092383; http://dx.doi.org/10.1146/annurev-med-112311-083918
   PubMed Web of Science ®Google Scholar
• Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014; 11:24-37; PMID:24247168; http://dx.doi.org/10.1038/nrclinonc.2013.208
   PubMed Web of Science ®Google Scholar
• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med 2016; 8:328rv4; PMID:26936508; http://dx.doi.org/10.1126/scitranslmed.aad7118
   PubMed Web of Science ®Google Scholar
• Cimino-Mathews A, Foote JB, Emens LA. Immune targeting in breast cancer. Oncology 2015; 29:375-85; PMID:25979549
   PubMed Web of Science ®Google Scholar
• Curti BD, Urba WJ. Clinical deployment of antibodies for treatment of melanoma. Mol Immunol 2015; 67:18-27; PMID:25746916; http://dx.doi.org/10.1016/j.molimm.2015.01.025
   PubMed Web of Science ®Google Scholar
• Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19:225-52; PMID:11244036; http://dx.doi.org/10.1146/annurev.immunol.19.1.225
   PubMed Web of Science ®Google Scholar
• Melero I, Berman DM, Aznar MA, Korman AJ, Perez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 2015; 15:457-72; PMID:26205340; http://dx.doi.org/10.1038/nrc3973
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol 2015; 33:1974-82; PMID:25605845; http://dx.doi.org/10.1200/JCO.2014.59.4358
   PubMed Web of Science ®Google Scholar
• Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009; 9:271-85; PMID:19319144; http://dx.doi.org/10.1038/nri2526
   PubMed Web of Science ®Google Scholar
• Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res 2013; 19:1044-53; PMID:23460535; http://dx.doi.org/10.1158/1078-0432.CCR-12-2065
   PubMed Web of Science ®Google Scholar
• Linch SN, McNamara MJ, Redmond WL. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol 2015; 5:34; PMID:25763356; http://dx.doi.org/10.3389/fonc.2015.00034
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Pastor F, Rodriguez A, Perez-Gracia JL, Rodriguez-Ruiz ME, Jure-Kunkel M, Melero I. Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Oncol 2015; 42:640-55; PMID:26320067; http://dx.doi.org/10.1053/j.seminoncol.2015.05.014
   PubMed Web of Science ®Google Scholar
• Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005; 23:23-68; PMID:15771565; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115839
   PubMed Web of Science ®Google Scholar
• Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003; 3:609-20; PMID:12974476; http://dx.doi.org/10.1038/nri1148
   PubMed Web of Science ®Google Scholar
• Redmond WL, Weinberg AD. Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Crit Rev Immunol 2007; 27:415-36; PMID:18197805; http://dx.doi.org/10.1615/CritRevImmunol.v27.i5.20
   PubMed Web of Science ®Google Scholar
• Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 2004; 4:420-31; PMID:15173831; http://dx.doi.org/10.1038/nri1371
   PubMed Web of Science ®Google Scholar
• Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 2013; 73:7189-98; PMID:24177180; http://dx.doi.org/10.1158/0008-5472.CAN-12-4174
   PubMed Web of Science ®Google Scholar
• Houot R, Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 2009; 113:3546-52; PMID:18941113; http://dx.doi.org/10.1182/blood-2008-07-170274
   PubMed Web of Science ®Google Scholar
• Linch SN, Kasiewicz MJ, McNamara MJ, Hilgart-Martiszus IF, Farhad M, Redmond WL. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. Proc Natl Acad Sci U S A 2016; 113:E319-27; PMID:26729864; http://dx.doi.org/10.1073/pnas.1510518113
   PubMed Web of Science ®Google Scholar
• Guo Z, Wang X, Cheng D, Xia Z, Luan M, Zhang S. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS One 2014; 9:e89350; PMID:24586709; http://dx.doi.org/10.1371/journal.pone.0089350
   PubMed Web of Science ®Google Scholar
• Linch SN, Redmond WL. Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts. Oncoimmunology 2014; 3:e28245; PMID:25050194; http://dx.doi.org/10.4161/onci.28245
   PubMed Web of Science ®Google Scholar
• Redmond WL, Linch SN, Kasiewicz MJ. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Cancer Immunol Res 2014; 2:142-53; PMID:24778278; http://dx.doi.org/10.1158/2326-6066.CIR-13-0031-T
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16:91-102; PMID:19647220; http://dx.doi.org/10.1016/j.ccr.2009.06.018
   PubMed Web of Science ®Google Scholar
• Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol 2014; 35:51-60; PMID:24210163; http://dx.doi.org/10.1016/j.it.2013.10.001
   PubMed Web of Science ®Google Scholar
• Schietinger A, Delrow JJ, Basom RS, Blattman JN, Greenberg PD. Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 2012; 335:723-7; PMID:22267581; http://dx.doi.org/10.1126/science.1214277
   PubMed Web of Science ®Google Scholar
• Redmond WL, Sherman LA. Peripheral tolerance of CD8 T lymphocytes. Immunity 2005; 22:275-84; PMID:15780985; http://dx.doi.org/10.1016/j.immuni.2005.01.010
   PubMed Web of Science ®Google Scholar
• Safford M, Collins S, Lutz MA, Allen A, Huang CT, Kowalski J, Blackford A, Horton MR, Drake C, Schwartz RH, et al. Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol 2005; 6:472-80; PMID:15834410; http://dx.doi.org/10.1038/ni1193
   PubMed Web of Science ®Google Scholar
• Jeon MS, Atfield A, Venuprasad K, Krawczyk C, Sarao R, Elly C, Yang C, Arya S, Bachmaier K, Su L, et al. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 2004; 21:167-77; PMID:15308098; http://dx.doi.org/10.1016/j.immuni.2004.07.013
   PubMed Web of Science ®Google Scholar
• Redmond WL, Gough MJ, Weinberg AD. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo. Eur J Immunol 2009; 39:2184-94; PMID:19672905; http://dx.doi.org/10.1002/eji.200939348
   PubMed Web of Science ®Google Scholar
• Wang B, Zaidi N, He LZ, Zhang L, Kuroiwa JM, Keler T, Steinman RM. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res 2012; 14:R39; PMID:22397502; http://dx.doi.org/10.1186/bcr3135
   PubMed Web of Science ®Google Scholar
• Redmond WL, Triplett T, Floyd K, Weinberg AD. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression. PLoS One 2012; 7:e34467; PMID:22496812; http://dx.doi.org/10.1371/journal.pone.0034467
   PubMed Web of Science ®Google Scholar
• Johannsen A, Genolet R, Legler DF, Luther SA, Luescher IF. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice. J Immunol 2010; 185:3445-55; PMID:20733200; http://dx.doi.org/10.4049/jimmunol.1001397
   PubMed Web of Science ®Google Scholar
• Gonzalez-Martin A, Gomez L, Lustgarten J, Mira E, Manes S. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res 2011; 71:5455-66; PMID:21715565; http://dx.doi.org/10.1158/0008-5472.CAN-11-1687
   PubMed Web of Science ®Google Scholar
• Kim TK, St John LS, Wieder ED, Khalili J, Ma Q, Komanduri KV. Human late memory CD8+ T cells have a distinct cytokine signature characterized by CC chemokine production without IL-2 production. J Immunol 2009; 183:6167-74; PMID:19841187; http://dx.doi.org/10.4049/jimmunol.0902068
   PubMed Web of Science ®Google Scholar
• Grange M, Verdeil G, Arnoux F, Griffon A, Spicuglia S, Maurizio J, Buferne M, Schmitt-Verhulst AM, Auphan-Anezin N. Active STAT5 regulates T-bet and eomesodermin expression in CD8 T cells and imprints a T-bet-dependent Tc1 program with repressed IL-6/TGF-beta1 signaling. J Immunol 2013; 191:3712-24; PMID:24006458; http://dx.doi.org/10.4049/jimmunol.1300319
   PubMed Web of Science ®Google Scholar
• Wolchok JD. PD-1 Blockers. Cell 2015; 162:937; PMID:26317459; http://dx.doi.org/10.1016/j.cell.2015.07.045
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 2014; 6:232ra51; PMID:24739759; http://dx.doi.org/10.1126/scitranslmed.3008068
   PubMed Web of Science ®Google Scholar
• Ascierto ML, Melero I, Ascierto PA. Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. Front Oncol 2015; 5:152; PMID:26217587; http://dx.doi.org/10.3389/fonc.2015.00152
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; http://dx.doi.org/10.1016/j.immuni.2013.07.004
   PubMed Web of Science ®Google Scholar
• Burotto M, Singh N, Heery CR, Gulley JL, Madan RA. Exploiting synergy: immune-based combinations in the treatment of prostate cancer. Front Oncol 2014; 4:351; PMID:25566495; http://dx.doi.org/10.3389/fonc.2014.00351
   PubMedGoogle Scholar
• van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 2016; 16(4):219-33; PMID:26965076; http://dx.doi.org/10.1038/nrc.2016.16
   PubMed Web of Science ®Google Scholar
• Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, Liu W, Cook DN, Portnoy DA, Dubensky TW, Jr. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A 2004; 101:13832-7; PMID:15365184; http://dx.doi.org/10.1073/pnas.0406035101
   PubMed Web of Science ®Google Scholar
• Crittenden M, Kohrt H, Levy R, Jones J, Camphausen K, Dicker A, Demaria S, Formenti S. Current clinical trials testing combinations of immunotherapy and radiation. Seminars Radiation Oncol 2015; 25:54-64; http://dx.doi.org/10.1016/j.semradonc.2014.07.003
   PubMed Web of Science ®Google Scholar
• Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 2015; 1:1325-32; PMID:26270858; http://dx.doi.org/10.1001/jamaoncol.2015.2756
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 2015; 28:690-714; PMID:26678337; http://dx.doi.org/10.1016/j.ccell.2015.10.012
   PubMed Web of Science ®Google Scholar